drug pi-88, melanoma; how good is it?, page-3

So, that's it then? No, it isn't.
Febr 1:

"The fourth and final Phase II trial of the series will be used as an adjuvant single agent therapy in post-operative liver cancer patients (conducted by Medigen
Biotechnology Corporation -Taiwan)".

So, summarizing, using drug PI-88:

Myeloma: Phase II completed.
Melanoma: Phase II has started.
Non-small cell lung cancer (NSCLC)". -Phase II has started.

Post-operative liver cancer patients: Phase II to be announced yet (Taiwan).
_________________________________

PGL also has drug PI-166-Liver Cancer:
Jan.13, 2003:

"Progen Industries (ASX:PGL) (NASDAQ:PGLAF) has commenced a Phase 1b human trial with anti-cancer agent PI-166 at the St George Hospital
in Sydney in patients with inoperable primary liver cancer (hepatoma).

The Principal Investigator for the trial is leading liver
surgeon Professor David Morris from the University of New South Wales (UNSW).

The objective of the trial will be to determine the safety and tolerability of a single localised delivery of PI-166 to the affected liver. The trial is expected to take one year and involve approximately 20-30 patients.

PI-166 is a small organic compound with specific avidity to liver cancer cells. In preclinical studies conducted by Professor Morris and pharmacologist Dr Mohammad Pourgholami, the compound demonstrated the ability to reduce the growth of rat hepatomas, which like human
hepatomas, are resistant to established anti-cancer agents".

Comment: Not an easy task. We may well hear something about the outcome in March-May?

Gerry